LENSAR, Inc. (NASDAQ: LNSR) reported Q1 EPS of ($0.56), $0.23 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $7 million versus the consensus estimate of $6.11 million.

“2021 is off to an encouraging start as we have continued to build on the positive trends seen in the second half of last year and achieved growth in both total revenues and procedures sold in the first quarter of 2021 compared to the first quarter of 2020,” said Nick Curtis, Chief Executive Officer of LENSAR. “While we still face challenges resulting from the COVID-19 pandemic, especially outside the U.S., we are seeing favorable signs toward a return of premium cataract procedures to pre-pandemic levels in the United States. In addition, we continue to make good progress on our next-generation system, ALLY™. Feedback from the ophthalmic community has been extremely enthusiastic. We look forward to showcasing ALLY at the ASCRS Annual Meeting, which is currently scheduled to take place in-person in July 2021.”

For earnings history and earnings-related data on LENSAR, Inc. (LNSR) click here.